The Moderna and AstraZeneca vaccine trials did not recruit a sufficient number of persons with a previous SARS-CoV-2 infection to report on whether adverse effects were different to those reported without prior infection. However, the available data do not show a safety signal.
Vaccination may be offered regardless of a person’s history of symptomatic or asymptomatic SARS-CoV-2 infection. There are not sufficient data to recommend the interval between a documented SARS-CoV-2 infection and vaccination. The added protection of vaccinating previously infected individuals is yet to be established. Currently available data indicate that symptomatic reinfection within 6 months after an initial infection is rare. Thus, persons with PCR-confirmed SARS-CoV-2 infection in the preceding 6 months may delay vaccination until near the end of this period. When more data on duration of immunity after natural infection become available, the length of this time period may be revised.
WHO does not recommend pre-vaccination screening for prior infection.